Results 31 to 40 of about 131,375 (266)

Frequency of Bone Mineral Density Testing in Adult Kidney Transplant Recipients from Ontario, Canada: A Population-Based Cohort Study

Canadian Journal of Kidney Health and Disease, 2016
Background: We lack consensus on the clinical value, frequency, and timing of bone mineral density (BMD) testing in kidney transplant recipients. This study sought to determine practice patterns in BMD testing across kidney transplant centres in Ontario,
Kyla L. Naylor, Guangyong Zou, William D. Leslie, Eric McArthur, Ngan N. Lam, Gregory A. Knoll, S. Joseph Kim, Lisa-Ann Fraser, Jonathan D. Adachi, Anthony B. Hodsman, Amit X. Garg   +10 more
doaj   +1 more source

Distinct Phenotypes of Non-Citizen Kidney Transplant Recipients in the United States by Machine Learning Consensus Clustering

Medicines, 2023
Background: Better understanding of the different phenotypes/subgroups of non-U.S. citizen kidney transplant recipients may help the transplant community to identify strategies that improve outcomes among non-U.S.
Charat Thongprayoon, Pradeep Vaitla, Caroline C. Jadlowiec, Napat Leeaphorn, Shennen A. Mao, Michael A. Mao, Fahad Qureshi, Wisit Kaewput, Fawad Qureshi, Supawit Tangpanithandee, Pajaree Krisanapan, Pattharawin Pattharanitima, Prakrati C. Acharya, Pitchaphon Nissaisorakarn, Matthew Cooper, Wisit Cheungpasitporn   +15 more
doaj   +1 more source

Deep Sequencing of FLT3‐ITD Enables Response Evaluation and Post‐Treatment Monitoring in Childhood AML: An Exploratory Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background An internal tandem duplication in the gene encoding Fms‐like tyrosine kinase 3 (FLT3‐ITD) is associated with high relapse risk and poor prognosis in acute myeloid leukemia (AML) and plays a crucial role in treatment decisions. Measurable residual disease (MRD) analysis of FLT3‐ITD during and after treatment has shown prognostic ...
Sofie Johansson Alm, Bea Tornberg, Erik Delsing Malmberg, Henrik Hasle, Kristian Løvvik Juul‐Dam, Lars Palmqvist, Borhan R. Saeed, Giti Shah Barkhordar, Anastasia Soboli, Anna Staffas, Jonas Abrahamsson, Linda Fogelstrand   +11 more
wiley   +1 more source

Heterogeneity in the Global Practice of Central Nervous System Staging in Pediatric Acute Lymphoblastic Leukemia

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Central nervous system (CNS) involvement in childhood acute lymphoblastic leukemia (ALL) is assessed by cell counting and cytomorphology from cerebrospinal fluid (CSF) and is used for treatment stratification worldwide. The ratio of “CNS2” patients in clinical trials ranges from 3% to 40%, with unclear prognostic significance ...
Laura Almási, Bernadett Borbála Huszti, Gábor Barna, Marko Kavcic, Janez Jazbec, Lennart Lenk, Vera Münch, Sophia Polychronopoulou, Ágnes Márk, Maria Thastrup, Lüder H. Meyer, Kjeld Schmiegelow, Cornelia Eckert, Christina Halsey, Dániel J. Erdélyi   +14 more
wiley   +1 more source

Emapalumab for Immune Effector Cell‐Associated Hemophagocytic Lymphohistiocytosis‐Like Syndrome Following CD19‐Directed CAR‐T in Two Patients With B‐ALL: Clinical and Biomarker Correlates

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Immune effector cell‐associated hemophagocytic lymphohistiocytosis‐like syndrome (IEC‐HS) is a life‐threatening hyperinflammatory toxicity distinct from cytokine release syndrome (CRS) and neurotoxicity following chimeric antigen receptor T‐cell (CAR‐T) therapy. In a single‐institution retrospective cohort of pediatric and young adult patients
Thomas J. Galletta, Jeremy D. Rubinstein, Christopher E. Dandoy, Ruby Khoury, Angela Faulhaber, Christine L. Phillips, Christa Krupski   +6 more
wiley   +1 more source

Host-microbe multiomic profiling identifies distinct COVID-19 immune dysregulation in solid organ transplant recipients

Nature Communications
Coronavirus disease 2019 (COVID-19) poses significant risks for solid organ transplant recipients, who have atypical but poorly characterized immune responses to infection.
Harry Pickering, Joanna Schaenman, Hoang Van Phan, Cole Maguire, Alexandra Tsitsiklis, Nadine Rouphael, Nelson Iván Agudelo Higuita, Mark A. Atkinson, Scott Brakenridge, Monica Fung, William Messer, IMPACC Network, Ramin Salehi-rad, Matthew C. Altman, Patrice M. Becker, Steven E. Bosinger, Walter Eckalbar, Annmarie Hoch, Naresh Doni Jayavelu, Seunghee Kim-Schulze, Meagan Jenkins, Steven H. Kleinstein, Florian Krammer, Holden T. Maecker, Al Ozonoff, Joann Diray-Arce, Albert Shaw, Lindsey Baden, Ofer Levy, Elaine F. Reed, Charles R. Langelier   +30 more
doaj   +1 more source

The Role of Hematopoietic Cell Transplantation in Ataxia‐Telangiectasia

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Ataxia‐telangiectasia (A‐T) is a DNA repair disorder characterized by neurodegeneration, immunodeficiency, and cancer predisposition. Hematopoietic cell transplantation (HCT) is an established therapy in related disorders such as Fanconi anemia (FA) and Nijmegen breakage syndrome (NBS), but its role in A‐T is unclear.
Laila Alkhouli, Seth Rotz, Masatoshi Takagi, Richa Sharma   +3 more
wiley   +1 more source

Safety and prognostic value of regadenoson stress cardiovascular magnetic resonance imaging in heart transplant recipients

Journal of Cardiovascular Magnetic Resonance, 2019
Background There is a critical need for non-invasive methods to detect coronary allograft vasculopathy and to risk stratify heart transplant recipients.
Felipe Kazmirczak, Prabhjot S. Nijjar, Lei Zhang, Andrew Hughes, Ko-Hsuan Amy Chen, Osama Okasha, Cindy M. Martin, Mehmet Akçakaya, Afshin Farzaneh-Far, Chetan Shenoy   +9 more
doaj   +1 more source

SARS-CoV-2 infection in the heart transplant recipient

Heart Views, 2020
Review of the literature and reported case series has not reported an increased risk of SARS-CoV-2 infection in heart transplant recipients. However, this population is at increased risk of a more severe infection with increased mortality because of age ...
Jassim Zaheen Shah, Salah Elbdri, Ashfaq Ahmad Patel, Amr Mohamed Hamed Badr   +3 more
doaj   +1 more source

Efficacy and Safety Analysis of Roxarestat in Regulating Renal Anemia in Patients on Maintenance Hemodialysis

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Objective To compare the efficacy and safety of roxarestat versus recombinant human erythropoietin (rhEPO) in the management of renal anemia in patients undergoing maintenance hemodialysis. Methods This was a prospective, open‐label, randomized controlled trial.
Lingling Chen, Junjie Zhu, Qiaonan Ge
wiley   +1 more source